{"disease":{"id":"lymphoid-malignancies","name":"lymphoid malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04329728","title":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"AVM Biotechnology Inc","has_results":false},{"nct_id":"NCT02223598","title":"A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"Cleave Biosciences, Inc.","has_results":false},{"nct_id":"NCT02569476","title":"BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT04283006","title":"A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"He Huang","has_results":false},{"nct_id":"NCT01947140","title":"Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Jennifer Amengual","has_results":false},{"nct_id":"NCT07472972","title":"Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT03056339","title":"Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT00529438","title":"RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT00788684","title":"Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02091063","title":"ACY-1215 for Relapsed/Refractory Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Jennifer Amengual","has_results":true},{"nct_id":"NCT05170568","title":"PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":22,"lead_sponsor_name":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04626908","title":"Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"He Huang","has_results":false},{"nct_id":"NCT07338604","title":"Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT01566656","title":"Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT05822843","title":"A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Shanghai Escugen Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT06732492","title":"RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT06761586","title":"A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Aurigene Discovery Technologies Limited","has_results":false},{"nct_id":"NCT05371054","title":"Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04880564","title":"A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Curon Biopharmaceutical (Australia) Co Pty Ltd","has_results":false},{"nct_id":"NCT02181478","title":"Intra-Osseous Co-Transplant of UCB and hMSC","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01596127","title":"Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02739360","title":"Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Gilead Sciences","has_results":true}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}